Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism

Behavioural Brain Research

Volumn 184, Issue 1, 2007, Pages 11-18

  Senthilkumar, Karuppagounder S ^a   Saravanan, Karuppagounder S ^a   Chandra, Goutam ^a   Sindhu, Kizhakke M ^a   Jayakrishnan, A ^b   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

6 Hydroxydopamine; Apomorphine; Controlled release; Dextran dialdehyde cross linked gelatin hydrogel; Dopamine; Parkinson's disease; Rotational behavior; Striatal implantation

Indexed keywords

APOMORPHINE; DEXTRAN DERIVATIVE; DEXTRAN DIALDEHYDE; DOPAMINE; GELATIN; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABLE IMPLANT; CIRCLING BEHAVIOR; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DOPAMINE RELEASE; DRUG DELIVERY SYSTEM; DRUG IMPLANTATION; DRUG RELEASE; EXPERIMENTAL MODEL; HYDROGEL; INJECTION SITE; MALE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ABSORBABLE IMPLANTS; ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; FUNCTIONAL LATERALITY; MALE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; ROTAROD PERFORMANCE TEST; STEREOTYPED BEHAVIOR; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 34548668709     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.06.025     Document Type: Article

References (36)

1. Aebischer P., Winn S.R., Tresco P.A., Jaeger C.B., and Greene L.A. Transplantation of polymer encapsulated neurotransmitter secreting cells: effect of the encapsulation technique. J Biomech Eng 113 (1991) 178-183
2. Balakrishnan B., and Jayakrishnan A. Self-cross-linking biopolymers as injectable in situ forming biodegradable scaffolds. Biomaterials 26 (2005) 3941-3951
3. Bakshi A., Fisher O., Dagci T., Himes B.T., Fischer I., and Lowman A. Mechanically engineered hydrogel scaffolds for axonal growth and angiogenesis after transplantation in spinal cord injury. J Neurosurg Spine 1 (2004) 322-329
4. Becker J.B., Robinson T.E., Barton P., Sintov A., Siden R., and Levy R.J. Sustained behavioral recovery from unilateral nigrostriatal damage produced by the controlled release of dopamine from a silicone polymer pellet placed into the denervated striatum. Brain Res 508 (1990) 60-64
5. Brown L.R., Wei C.L., and Langer R. In vivo and in vitro release of macromolecules from polymeric drug delivery systems. J Pharm Sci 72 (1983) 1181-1185
6. Cadee J.A., van Luyn M.J., Brouwer L.A., Plantinga J.A., van Wachem P.B., de Groot C.J., et al. In vivo biocompatibility of dextran-based hydrogels. J Biomed Mater Res 50 (2000) 397-404
7. Chandra G., Gangopadhyay P.K., Senthil Kumar K.S., and Mohanakumar K.P. Acute intranigral homocysteine administration produces stereotypic behavioural changes and striatal dopamine depletion in Sprague-Dawley rats. Brain Res 1075 (2006) 81-92
8. Cortesi R., Esposito E., Osti M., Squarzoni G., Menegatti E., Davis S.S., et al. Dextran cross-linked gelatin microspheres as a drug delivery system. Eur J Pharm Biopharm 47 (1999) 153-160
9. Doucet G., Descarries L., and Garcia S. Quantification of the dopamine innervation in adult rat neostriatum. Neuroscience 19 (1986) 427-445
10. Draye J.P., Delaey B., Voorde A.V., Bulcke A.V., Bogdanov B., and Schacht E. In vitro release characteristics of bioactive molecules from dextran dialdehyde cross-linked gelatin hydrogel films. Biomaterials 19 (1998) 99-107
11. Draye J.P., Delaey B., Voorde A.V., Bulcke A.V., Reu B., and Schacht E. In vitro and in vivo biocompatibility of dextran dialdehyde cross-linked gelatin hydrogel films. Biomaterials 19 (1998) 1677-1687
12. During M.J., Freese A., Deutch A.Y., Kibat P.G., Sabel B.A., Langer R., et al. Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes. Exp Neurol 115 (1992) 193-199
13. Emerich D.F., McDermott P.E., Krueger P.M., Frydel B., Sanberg P.R., and Winn S.R. Polymer-encapsulated PC12 cells promote recovery of motor function in aged rats. Exp Neurol 122 (1993) 37-47
14. Ghorayeb P.O., Fernagut L., Hervier L., Labattu B., Bioulac B., and Tison F. A 'single toxin-double lesion' rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis. Neuroscience 115 (2002) 533-546
15. Haycock J.W. Stimulation-dependent phosphorylation of tyrosine hydroxylase in rat corpus striatum. Brain Res Bull 19 (1987) 619-622
16. Hely M.A., Morris J.G., Reid W.G., O'Sullivan D.J., Williamson P.M., Rail D., et al. The Sydney multicentre study of Parkinson's disease: a randomised, prospective 5 years study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatr 57 (1994) 903-910
17. Kim D.H., and Martin D.C. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials 27 (2006) 3031-3037
18. Lesny P., De Croos J., Pradny M., Vacik J., Michalek J., Woerly S., et al. Polymer hydrogels usable for nervous tissue repair. J Chem Neuroanat 23 (2002) 243-247
19. McRae-Degueurce A., Hjorth S., Dillon D.L., Mason D.W., and Tice T.R. Implantable microencapsulated dopamine (DA): a new approach for slow-release DA delivery into brain tissue. Neurosci Lett 92 (1988) 303-309
20. Marsden C.D., Parkes J.D., and Quinn N. Fluctuations in disability in Parkinson's disease-clinical aspects. In: Marsden C.D., and Fahn S. (Eds). Movement disorders (1981), Butterworths, London 96-122
21. Moore A.E., Cicchetti F., Hennen J., and Isacson O. Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat. Exp Neurol 172 (2001) 363-376
22. Muralikrishnan D., and Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice. FASEB J 12 (1998) 905-912
23. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1998), Academic Press, San Diego p. 117
24. Robinson T.E., Becker J.B., and Presty S.K. Long-term facilitation of amphetamine-induced rotational behavior and striatal dopamine release produced by a single exposure to amphetamine: sex differences. Brain Res 253 (1982) 231-241
25. Sachs C., and Jonsson G. Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol 24 (1975) 1-8
26. Sajadi A., Bensadoun J.C., Schneider B.L., Lo Bianco C., and Aebischer P. Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson's disease. Neurobiol Dis 22 (2006) 119-129
27. Saravanan K.S., Sindhu K.M., and Mohanakumar K.P. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res 1049 (2005) 147-155
28. Schwarting R.K., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50 (1996) 275-331
29. Sindhu K.M., Saravanan K.S., and Mohanakumar K.P. Behavioural differences in a rotenone-induced hemiparkinsonian rat model developed following intra-nigral or median forebrain bundle infusion. Brain Res 1051 (2005) 25-34
30. + or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacol Biochem Behav 84 (2006) 321-329
31. Stromberg I., Herrera-Marschitz M., Ungerstedt U., Ebendal T., and Olson L. Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behavior. Exp Brain Res 60 (1985) 335-349
32. Tian W.M., Hou S.P., Ma J., Zhang C.L., Xu Q.Y., Lee I.S., et al. Hyaluronic acid-poly-d-lysine-based three-dimensional hydrogel for traumatic brain injury. Tissue Eng 11 (2005) 513-525
33. Tresco P.A., Winn S.R., Tan S., Jaeger C.B., Green L.A., and Aebischer P. Polymer-encapsulated PC12 cells: long-term survival and associated reduction in lesion-induced rotational behavior. Cell Transplant 1 (1992) 255-264
34. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367 (1971) 95-122
35. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24 (1970) 485-493
36. Winn S.R., Wahlberg L., Tresco P.A., and Aebischer P. An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in rats. Exp Neurol 105 (1989) 244-250